1-4 of 4
Hiraku Itadani
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Abstract P020: Schlafen 11 (SLFN11) as a predictive biomarker of the response to TAS1553, a novel small molecule ribonucleotide reductase subunit interaction inhibitor

Hiroto Fukushima, Hiroyuki Ueno, Takuya Hoshino, Wakako Yano, Hiraku Itadani, Miki Terasaka, Sayaka Tsukioka, Takamasa Suzuki, Shoki Hara, Yoshio Ogino, Khoon Tee Chong, Tatsuya Suzuki, Yoshihiro Otsu, Satoshi Ito, Nozomu Tanaka, Seiji Miyahara
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2021) 20 (12_Supplement): P020.
https://doi.org/10.1158/1535-7163.TARG-21-P020
Published: 01 December 2021
View article titled, Abstract P020: Schlafen 11 (SLFN11) as a predictive biomarker of the response to TAS1553, a novel small molecule ribonucleotide reductase subunit interaction inhibitor
Journal Articles

Abstract A126: Acquired resistance to trastuzumab/pertuzumab, or to T-DM1 in vivo can be overcome by HER2 inhibition with TAS0728

Hiroki Irie, Rumi Kawabata, Yayoi Fujioka, Fumio Nakagawa, Hideki Nagase, Hiraku Itadani, Kimihiro Ito, Junji Uchida, Shuichi Ohkubo, Kenichi Matsuo, Takeshi Sagara, Teruhiro Utsugi
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2019) 18 (12_Supplement): A126.
https://doi.org/10.1158/1535-7163.TARG-19-A126
Published: 01 December 2019
View article titled, Abstract A126: Acquired resistance to trastuzumab/pertuzumab, or to T-DM1 <em>in vivo</em> can be overcome by HER2 inhibition with TAS0728
Journal Articles

Small-molecule inhibition of Wee1 kinase by MK-1775 selectively sensitizes p53-deficient tumor cells to DNA-damaging agents

Hiroshi Hirai, Yoshikazu Iwasawa, Megumu Okada, Tsuyoshi Arai, Toshihide Nishibata, Makiko Kobayashi, Toshifumi Kimura, Naoki Kaneko, Junko Ohtani, Kazunori Yamanaka, Hiraku Itadani, Ikuko Takahashi-Suzuki, Kazuhiro Fukasawa, Hiroko Oki, Tadahiro Nambu, Jian Jiang, Takumi Sakai, Hiroharu Arakawa, Toshihiro Sakamoto, Takeshi Sagara, Takashi Yoshizumi, Shinji Mizuarai, Hidehito Kotani
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2009) 8 (11): 2992–3000.
https://doi.org/10.1158/1535-7163.MCT-09-0463
Published: 10 November 2009
View article titled, Small-molecule inhibition of Wee1 kinase by MK-1775 selectively sensitizes p53-deficient tumor cells to DNA-damaging agents
Open the PDF for Small-molecule inhibition of Wee1 kinase by MK-1775 selectively sensitizes p53-deficient tumor cells to DNA-damaging agents in another window
Includes: Supplementary data
Journal Articles

Expression levels of p18INK4C modify the cellular efficacy of cyclin-dependent kinase inhibitors via regulation of Mcl-1 expression in tumor cell lines

Tomohiro Eguchi, Hiraku Itadani, Toshiyasu Shimomura, Nobuhiko Kawanishi, Hiroshi Hirai, Hidehito Kotani
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2009) 8 (6): 1460–1472.
https://doi.org/10.1158/1535-7163.MCT-08-1159
Published: 10 June 2009
View article titled, Expression levels of p18<sup>INK4C</sup> modify the cellular efficacy of cyclin-dependent kinase inhibitors via regulation of Mcl-1 expression in tumor cell lines
Open the PDF for Expression levels of p18<sup>INK4C</sup> modify the cellular efficacy of cyclin-dependent kinase inhibitors via regulation of Mcl-1 expression in tumor cell lines in another window
Includes: Supplementary data